Antibody-Drug Conjugate (ADC) is a next-generation technology that effectively removes cancer cells by combining oncology drugs with antibodies that selectively attack cancer cells. Celltrion is currently collaborating with Global Pharm to develop ADC bio betters targeting various tumors.
Structure of ADC
- ADED Platform
The ADC bio better currently under development by Celltrion utilizes Antibody Delivery Enhancing Domain (ADED). This platform technology increases the delivery efficiency of the antibody-drug conjugates and their cell penetration, which greatly enhances treatments.
We expect that our ADC products will be effective for breast cancer patients regardless of HER-2 incidence rates. Moreover, we hope to expand the target antigens of the antibodies to include other tumor-associated antigens by applying ADC technology.